Oral News and Research

RSS

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

MAP Pharmaceuticals, Inc. today announced that the Company will present nine analyses relating to its LEVADEX™ orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

Generex announces participation in Annual Canadian Diabetes Association Conference

Generex Biotechnology Corporation today announced that it will be attending the 13th Annual Canadian Diabetes Association (CDA)/ Canadian Society of Endocrinology and Metabolism (CSEM)Professional Conference and Annual Meetings in Edmonton, Alberta. The gathering will run from October 20-23, 2010 at the Shaw Conference Centre.

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

New model for rural clinics in underserved areas

The University of Maryland Dental School Clinic, Perryville is a new model for rural clinics in underserved areas across the country, says Christian S. Stohler, DMD, DrMedDent, dean of the Dental School in Baltimore.

20 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Curcumin, the major component in the spice turmeric, when combined with the drug Cisplatin enhances the chemotherapy's suppression of head and neck cancer cell growth, researchers with UCLA's Jonsson Cancer Center have found.

20 Oct 2010

Experts at Ninth International Symposium discuss health effects and safety of S-equol

The latest research into the health effects and safety of a soy-based compound called S-equol was described in talks and presentations by experts at a special session on Tuesday, Oct. 19 during the Ninth International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment, held Oct. 16 to 19 in Washington, D.C.

20 Oct 2010

Salix acquires rights to colon cancer screening agent from Photocure

Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.

20 Oct 2010

Osteoporosis drug heals bone wounds in gum disease patients

A drug marketed to grow bone in osteoporosis patients also works to heal bone wounds in gum disease patients, a University of Michigan study suggests.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Lotus Pharmaceuticals, Inc.a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

First Edition: October 19, 2010

Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.

19 Oct 2010

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

HOYA ConBio™, a global leader in dental and aesthetic lasers, today announced an extension of its sponsorship agreement with the Las Vegas Institute for Advanced Dental Studies (LVI), the pioneer in live-patient, post-graduate dental training. The agreement ensures that VersaWave™ and DioDent™ Micro 980 lasers will continue to be featured at LVI's advanced teaching facilities through 2013.

19 Oct 2010

ADHA and GSK emphasize importance of proper brushing as key to maintaining oral health

With the theme "Healthy Habits are Easier than You Think" for its National Dental Hygiene Month (NDHM) celebration this October, the American Dental Hygienists' Association (ADHA), in collaboration with GlaxoSmithKline (GSK), makers of Aquafresh®, emphasizes the importance of proper brushing as a key to maintaining excellent oral health.

19 Oct 2010

Peer partner program helps diabetic patients to manage their conditions

Phone calls with a peer facing the same self-management challenges helped diabetes patients manage their conditions and improved their blood sugar levels better than those who used traditional nurse care management services alone, according to research from the University of Michigan Health System.

19 Oct 2010

Oral News and Research

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Generex announces participation in Annual Canadian Diabetes Association Conference

Genzyme third quarter revenue increases to $1.0 billion

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

New model for rural clinics in underserved areas

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Experts at Ninth International Symposium discuss health effects and safety of S-equol

Salix acquires rights to colon cancer screening agent from Photocure

Osteoporosis drug heals bone wounds in gum disease patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

First Edition: October 19, 2010

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

ADHA and GSK emphasize importance of proper brushing as key to maintaining oral health

Peer partner program helps diabetic patients to manage their conditions

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News